Dronabinol for Cannabis Use Disorder

This trial examines how men and women respond differently to cannabis, using dronabinol (a synthetic form of THC) to determine its effects on frequent cannabis users. Participants will visit the study center three times to receive either THC, the active component in cannabis, or a placebo. During these visits, they will complete questionnaires, undergo a brain scan, and one visit will include a blood draw for genetic testing. This trial is suitable for individuals aged 21-45 who use cannabis at least four days a week and are not currently seeking treatment for cannabis use. As a Phase 2 trial, this research measures the treatment's effectiveness in an initial, smaller group, allowing participants to contribute to significant findings in cannabis research.

Previous studies have shown that dronabinol, a synthetic version of THC (the main active component of cannabis), is generally safe for patients. The FDA has approved dronabinol for other uses, such as treating nausea in cancer patients and aiding appetite in individuals with HIV/AIDS. This approval indicates its safety when used correctly for these conditions.

Dronabinol is unique because it directly targets the endocannabinoid system, offering a novel approach to treating Cannabis Use Disorder (CUD). Unlike standard treatments like cognitive behavioral therapy or certain medications used off-label, dronabinol is a synthetic form of THC, the primary psychoactive component of cannabis, which may help reduce withdrawal symptoms and cravings. Researchers are excited about dronabinol because it could provide a targeted mechanism of action that directly addresses the neurochemical imbalances associated with cannabis dependency, potentially offering a more effective intervention than current options.

Studies have shown that dronabinol, a synthetic version of THC, can help reduce withdrawal symptoms for individuals trying to quit cannabis. Research also suggests it may improve the likelihood of remaining in treatment programs. In some cases, dronabinol has eased symptoms of cannabis dependence, making it a promising option for those with cannabis use disorder. Early findings indicate it could help manage cravings and lower the risk of relapse. Participants in this trial will receive dronabinol, with separate treatment arms for males and females to assess any differences in response.⁶⁷⁸⁹¹⁰